are inclined to deny the importance of rigorous avoidance and because their behaviour is unpredictable. Most fatalities due to anaphylactic reactions to peanut occur in adolescents or young adults, 24 who therefore need strategies to protect them against this risk. Adolescents are able to ingest large-size capsules and therefore to follow a course of OIT. To date, there have been no documented findings on OIT in a population composed solely of adolescents with established peanut allergy and high levels of peanut-specific IgE.
The primary aim of this study was to assess the ability of this new modality of OIT to induce desensitization in peanut-allergic adolescents. The secondary aim was to analyse the AE and particularly those suspected of resulting from the bypassing the upper digestive tract during the build-up phase of the protocol. The desensitized patients were then included in the second phase of the study to evaluate sustained unresponsiveness after maintenance phase. They subsequently returned to a non-restrictive diet in daily life. We report here only the results of the build-up phase.
| METHODS
We conducted a randomized, double-blind, placebo-controlled, multicentre study to assess the efficacy and safety of GIDOIT in adolescents and to confirm the immunological mechanisms underlying this treatment and their relationship to clinical outcomes. 4 The study was , Thermo Fisher â ) for peanut or over 5.8 IU/mL for rAra h 2 fraction of peanut. 26, 27 Exclusion criteria were a history of severe anaphylaxis requiring hospitalization in an intensive care unit, severe persistent asthma or poorly controlled atopic dermatitis, lactose intolerance, allergy to sunflower (contained in the trial capsules), and the inability, for whatever reason, to manage a severe reaction. To avoid misinterpretation, the occurrence of another concomitant severe food allergy (such as to egg, milk or nuts)
was also an exclusion criterion. Patients having experienced a severe reaction after food ingestion are at risk of reproducing a severe systemic reaction whose origin would be difficult to differentiate from that of a peanut-induced reaction (Appendix S1; Figure 1 ).
All patients underwent a double-blinded placebo-controlled oral food challenge (DBPCFC) with sealed capsules (Table S1) (Table S2) while maintaining a peanut-free diet. The first dose of each increment was
given in the study centre by a nurse who was blinded. The patients were kept under surveillance for 2 hours before leaving the hospital.
On-going treatments were continued, particularly those for asthma management. Daily home intake of the capsules, the times at which they were taken and any AE were recorded in the patient's paper diary. Education sessions were mandatory before and during the protocol. Patients were instructed to remain under supervision for 2 hours after intake. The raw material used to prepare the peanut capsules by the pharmacy department was a paste made with roasted peanut from Argentina with sunflower oil added (MENGUY'S ©). Total protein content of the paste was %20% (Appendix S2).
Thus, we decided to present results in terms of pp to allow comparison with studies performed with defatted peanut powder containing around 50% protein.
To avoid mouth and oesophageal contacts, peanut paste was enclosed in sealed gelatin capsules to swallow, allowing allergen gastric/small intestine release. The main objective of the study was to investigate the efficacy and safety of oral escalating immunotherapy using a gastrointestinal delivery system with sealed capsules of peanut up to a maximum daily level of 400 mg of pp. The primary endpoint was assessed at a second DBPCFC performed one day (or 3 days at weekends) after the end of the build-up phase to allow the patient to return to baseline. This waiting period was included in the protocol to avoid cumulating the daily intake of 400 mg of pp and the intake of 2 to 1800 mg of pp during DBPCFC2.
Desensitization was considered to be achieved when no objective symptoms occurred after the ingestion of 400 cumulative mg of pp during DBPCFC2, that is, the reactivity threshold was strictly over 400 mg. Safety was assessed on the basis of the number and intensity of AE and the number of withdrawn patients (after grade 3b or grade 4 reactions or those whose level of intake remained unchanged for more than 8 weeks). 25 The secondary endpoints were the number of patients who increased 4-fold the tolerated dose of cumulative peanut intake during DBPCFC, the percentage of patients affected by AE and immunological profile changes. Adverse events were recorded at each visit to the department and classified as local (rhinitis, conjunctivitis, oropharyngeal symptoms and dysphagia), cutaneous, digestive or general (Table S3) , and if appropriate considered as a likely allergic reaction to the treatment. If any reaction occurred during the protocol, symptomatic drugs were prescribed, depending on the severity of the reaction. 25 The immunological profile was assessed at each DBPCFC and at mid build-up phase on the basis of SPT and total IgE and IgG4 levels, peanut-specific IgE and IgG4 levels for total peanut and the recombinant fractions rAra h 1, rAra h 2, rAra h 3, rAra h 8 and rAra h 9 (ImmunoCAP â , Phadia
In all, 60 randomized patients were necessary to detect a 50% difference in the primary outcome with a 2-sided type I error set at a = .05 and a statistical power of 90% assuming a 60% rate of desensitization after the build-up phase in the treated group and 10% in the placebo group with a 2:1 ratio. (Tables 1 and 2 ). The baseline immunologic profile of patients is given in Table S4 . No patients were suspected of gastro-oesophageal reflux. As required by the protocol, none of the patients included had a peanut threshold over 400 mg of cumulative pp.
| Primary outcome
Unresponsiveness to 400 cumulative mg of pp (2 cumulative grams of peanut) was achieved in 17 of the 21 patients treated with peanut and 1 of the 9 patients receiving placebo (Intention-to-treat analysis, P < .001, Fisher's exact test) ( Figure 3 ). Of these 30
patients, 2 in the treated group withdrew because of side effects (described below), leaving 28 to undergo DBPCFC2. Two patients both treated with peanut did not increase their intake threshold over 400 mg as targeted, which increased from 30 mg to 222 mg and from 62 mg to 400 mg. Thus, they failed the first outcome but succeeded in the second (increasing 4-fold their unresponsiveness threshold of cumulative intake). For these 2 patients, the number of 2-week step periods without AE was 6 and 11 out of 12. They tolerated the last 2-week steps when ingesting the daily amount of 400 mg of pp without AE. The one patient whose threshold increased under placebo did not complain of any AE during build-up phase but had a grade 3b reaction after ingesting 1800 mg of cumulated pp during DBPCFC2.
| Secondary outcomes
Between DBPCFC1 and DBPCFC2, the cumulated median pp (Table S5 ). The reactivity threshold was similar in the placebo and peanut groups at baseline (P = .38) but differed significantly (P < .001) at DBPCFC2. In total, 17 of the 19 patients treated with peanut who finished the build-up protocol increased their reactivity threshold 4-fold between DBPCFC1 and DBPCFC2 as did 2 out of 9 in the placebo group. The statistical significance was high in per-protocol analysis (P < .001) and also in intention-to-treat analysis (P < .001) ( Figure 3 ).
| Safety
Two patients from the peanut group did not complete the build-up phase, one because of a severe adverse event (SAE) (anaphylactic shock requiring Epinephrine) and the other because of moderate but recurrent respiratory side effects (grade 2) that led us to maintain the same level of peanut intake over 3 additional 2-week periods.
Only 3 patients had no adverse reaction at any time during the build-up phase, 2 in the peanut group and one in the placebo group.
The number of patients experiencing AE was not different between the 2 groups but the number of AEs per patient was higher in the treated group than in the control group, resulting in a higher number 
| Immunological profile
is shown in Table 2 . SPTs decreased from 12.4 AE 6.7 mm to 6.0 AE 4.0 mm between the 2 DBPCFCs (P < .001) in the peanut group as against 12.5 AE 6.6 mm to 8 AE 3.8 mm in the placebo group (P < .05). Positive histamine controls were unchanged (data not shown). None of the patients acquired sensitization to sunflower seeds during the study. In the peanut group, total IgE but not total against Ara h 9. No variation in peanut-specific IgE/total IgE ratio was observed during the build-up phase in either group ( Figure 4A ). In contrast, peanut and Ara h 2-specific IgG4/specific IgE ratios increased in the treated group at DBPCFC2, reaching significance for Ara h 2 (P = .03). There was no significant difference between the placebo and treated groups in IgG4/IgE ratios ( Figure 4B ,C). Foxp3 + regulatory T cells in the mesenteric lymph node and therefore to mediate T-cell suppression. 34 Thus, allergen delivery in the gut is theoretically a suitable route to induce tolerance. 35 Consequently, we decided to target directly the antigen towards the immune cells of the gut. This decision was also governed by the observation that carrying allergen directly to the gut of non-sensitized patients can induce greater sensitization than allergens initially digested in the stomach, probably because of a better conservation of the tri-dimensional structure of allergens. 36 Conversely, we hypothesized that the same reasoning, based on the use of better preserved allergens, would help in inducing desensitization in highly sensitized patients and probably limit the incidence of AE. In addition, using capsules could reduce the risk of oropharyngeal symptoms and of iatrogenic eosinophilic oesophagitis (see below). 18 The use of capsules rather than flour masks the taste of peanut and allows a true double-blind comparison of the groups, except in the event of a significant gastro-oesophago-pharyngeal reflux. Finally, ingesting capsules also avoids aversion, which is commonly encountered in peanut allergy. To our knowledge, using sealed peanut capsules has been tested in only one study on a small number of patients without placebo controls. it can be presumed that these patients are protected in daily life.
| DISCUSSION
However, at DBPCFC2, 2 patients (9.5%) remained intolerant to 400 mg of pp but had increased their threshold level 6-and 7-fold, respectively. Thus, they achieved the secondary outcome of a 4-fold increase in threshold. In addition, they succeeded in ingesting 400 mg daily of pp at home without any clinical symptoms. Although these 2 patients were not considered desensitized (because the first endpoint was not achieved), the impact of the treatment was manifest. Thus, the threshold progression cannot be considered to be a consequence of intra-individual variability. There are 3 possible explanations of the discrepancy between the day-to-day intake of peanut and the ingestion of peanut during DBPCFC2 in these 2 patients. (i) The modality of intake, which was instantaneous in dayto-day ingestion and cumulative during DBPCFC (Table S2) performed. The lack of reproducibility of the challenge could also account for this slight variation. 40 The overall rise in threshold in the placebo group (from 122 to 400 mg of pp) could have resulted from day-to-day intra-individual variability. We speculate that this variability could be due to criteria such as seasonal variability, reduced stress due to habituation to DBPCFC or other factors. While this is an important finding, what should be particularly emphasized is that, despite both groups being affected by seasonal or intra-individual variability, there was a great difference in intensity of the threshold increase between the two. Since biological arguments have been suggested by others for a secondary loss of unresponsiveness, the persistence of tolerance after OIT will be addressed in our protocol in the long term. 41 In the interest of safety, the management of AEs underwent rigorous assessment. The patients taking part had all attended education sessions, and before enrolment and at each visit they were tested on their knowledge of the practical management of their allergy. In both the treated and placebo groups they were able, therefore, to identify a wide range of side effects. 5 Unlike in other *P = mid build-up vs DBPCFC 1; **P = DBPCFC 2 vs DBPCFC 1; ***P = peanut patients vs placebo patients at DBPCFC2. DBPCFC, double-blind placebo-controlled oral food challenge; ND, not done; Plac., Placebo; SD, standard deviation; Spec., Specific.
types of AE, the number of local symptoms was not significantly different between treated and control patients. Interestingly, and in contrast to previous reports, oropharyngeal symptoms (swelling, itching and paraesthesia located in the oral sphere) in our study
were not significantly more frequent in treated patients. 7 Unfortunately, we did not assess quality of life and so are unable to evaluate the daily impact of the clinical effects observed. Gastrointestinal AEs, as in other studies, were frequent in our treated patients. 7 In all but one patient, repeating the same level of intake during an additional 2-week period, in some cases associated with antihistamine treatment, was sufficient to allow them to carry on with the escalation protocol. The median duration of the build-up phase was therefore 190 days (13. in a recent study using opened peanut capsules during which 21%
of the patients were withdrawn because of digestive side effects, mainly vomiting. 30 Most of them (4 ie 14%) were withdrawn primarily because they experienced recurrent digestive AEs. Two (7%) were withdrawn because of lack of compliance following digestive (and other) AEs. As we observed no compliance problems due to digestive symptoms, we speculate that adverse reactions were milder in our patients.
Severe AEs grade 3 were infrequent. Three patients experienced a total of 4 non-life-threatening reaction grade 3a. All promptly and fully recovered after symptomatic treatment at home without consultation of a physician or hospitalization. Thus, the AEs did not lead to withdrawal. The only patient who experienced a grade 3b reaction had not rigorously followed the protocol. At mid-day, 2 hours after ingestion and a physical workout, he experienced an anaphylactic reaction that required the intervention of the emergency service for administration of epinephrine. He received salbutamol, oral steroids and antihistamines. He fully recovered promptly, and was released from hospital in the afternoon. After being withdrawn from the study, the patient declared he had taken twice the prescribed dose of 100 mg of pp. Accidental double dosing is a commonly reported AE in other studies. This incident occurred despite patient selection and educational training programmes. Investigators should exercise caution with regard to this issue to avoid SAEs. This single incident (1 patient out of 21 = 4.8%) is to be compared with the 57 widely dispersed (from 0% to 31% of patients) reactions described by Wasserman in 36 of 352 patients recruited at 5 sites and treated with epinephrine during escalation. 43 The slow escalation of peanut intake and the education sessions provided for the management of AEs at their very early onset could account for the rareness of severe anaphylaxis in our treated patients. The relatively low rate of protein in our peanut paste could also partly explain the rareness of life-threatening AEs. Dirks et al 22 showed that absorption of dietary proteins by the buccal mucosae is very rapid, leading to blood histamine release in 10 minutes. The authors postulated that this F I G U R E 3 Peanut protein intake threshold at DBPCFC1 and DBPCFC2 (intention to treat analysis: P < .001): cumulated reaction dose at challenge (mg of peanut protein). In all, 30 adolescents underwent oral immunotherapy either with peanut capsules (n = 21) or with placebo capsules (n = 9). Two patients were withdrawn from the treated group (no DBPCFC2). DBPCFC2 was negative at 400 mg of pp in 17 of the 19 treated patients and one of the placebo patients (P < .001). (DBPCFC = double-blind placebocontrolled oral food challenge)
FAUQUERT ET AL.
| 869 absorption could explain the elicitation of food-induced systemic reactions. Moreover, another interesting study has showed that severe reactions occur mainly in the 30 minutes after swallowing the eliciting food. 44 In our patients, conversely, severe reactions were relatively rare and occurred within 40-120 minutes. The symptoms, such as urticaria, oedema and asthma, were typically IgE-mediated.
We speculate therefore that shunting the upper digestive tract is beneficial since it reduces absorption of allergens by the buccal mucosae and hence their release in the blood, which in turn reduces systemic reactions. 44 A second patient was excluded because she had moderate side effects (grade 2) that led us to maintain the same level of peanut intake over four 2-week periods. According to the statistical plan, the number of 2 withdrawn patients was compatible with continuing the 45, 46 In previous studies involving peanut OIT, an increase in specific IgE was observed as of 2 months of treatment and continued for at least 12-18 months. 5, 14, 47 This increase was also associated with a significant increase in specific IgG4 measurements.
However, although the IgG4 increase was highly significant in our peanut group, the intergroup assessment of variability did not reach significance for IgG4/IgE ratios in our mixed model, possibly owing to a lack of power consecutive to the great dispersion of values.
Analysis of the peanut paste used to prepare the capsules confirmed the presence in significant and stable amounts of 3 major peanut allergen fractions, Ara h 1, Ara h 2 and Ara h 3, in the raw material. This assay had to be performed before clinical challenge against these molecular compounds (Appendix S2). 48 At baseline, our patients were sensitized against Ara h 2 and to some extent against Ara h 1 and Ara h 3. In our patients, changes in the antibody response to the three allergenic fractions Ara h 1, Ara h 2 and Ara h 3 were similar to those of the total extract: a simultaneous increase in the specific IgE and specific IgG4 values and their IgG4/IgE ratio. F I G U R E 4 Immunological profile: (A) Ratio of peanut-specific IgE (IU/mL)/total IgE (IU/mL). The serum ratio of peanut-specific IgE over total IgE did not change significantly between DBPCFC1 and DBPCFC2 in the peanut group in comparison with the placebo group. (B) Ratio of peanut-specific IgG4 (lg/mL)/peanut-specific IgE (IU/mL). The ratio of peanut-specific IgG4 over specific IgE increased between DBPCFC1 and DBPCFC2 in the peanut group without reaching significance (P = .06). (C) Ratio of Ara h 2-specific IgG4 (lg/mL)/Ara h 2-specific IgE (IU/ mL). The ratio of Ara h 2-specific IgG4 over Ara h 2-specific IgE increased significantly (P = .03) in the peanut group between DBPCFC1 and DBPCFC2. Like the ratio of peanut antibodies (B), when compared with the placebo group this increase did not reach statistical significance. DBPCFC = double-blind placebo-controlled oral food challenge FAUQUERT ET AL.
| 871 observed dramatic changes in our treated patients in Ara h 2 levels of IgE and IgG4 after the build-up phase. The effects of the increase in the Ara h 2 ratio of IgG4/IgE after the build-up phase on the clinical sensitivity of patients to the intake of peanut could explain the rareness of severe AEs. The follow-up of immune status should help in managing the clinical course of patients and in predicting relapses. [54] [55] [56] Ara h 8-specific IgE levels cause a biological cross-reactivity with respiratory allergens of the PR10 family. 55 The differences observed at baseline between the peanut and placebo groups in the levels of anti-Ara h 8 IgE and IgG4 persisted at DBPCFC2. These differences were a consequence of high levels of anti-Ara h 8 IgE detected in 2 placebo patients. As expected, the anti-Ara h 9-specific IgE level did not change significantly between DBPCFC1 and DBPCFC2 in the peanut group, which is consistent with the rareness of the lipid transfer protein syndrome in our region (only 2 patients had specific anti-Ara h 9 IgE at baseline greater than 0.35 IU/mL).
The peanut-specific IgE/total IgE ratio did not change significantly, a stability that could be explained by the increase in total IgE levels, which counterbalance the increase in peanut-specific IgE levels.
Hence, the changes in the immune profile may not be restricted to immunity directed against peanut. We performed an ancillary study, therefore, using the immuno solid-phase allergen chip (ISAC) technique, to evaluate the impact of peanut GIDOIT on associated sensitizations (data not shown).
In conclusion, our study provides an effective standardized way to induce peanut desensitization in high-risk adolescents, offering them protection against severe anaphylactic reactions after unintended intake. The PITA trial showed a low incidence of oropharyngeal symptoms and no signs suggestive of eosinophilic oesophagitis.
In light of these findings, safety regarding local AEs is therefore enhanced by the administration of peanut paste in sealed capsules.
Owing to the low incidence of life-threatening AE, the trial have an acceptable safety profile. In addition masking the taste of peanut, using sealed capsules probably had a positive impact on compliance.
Further studies of larger populations are needed to confirm these results and to assess the long-term persistence of food tolerance. 
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